Laboratory Corporation of America Holdings (LH) Q4 2023 Earnings Call Transcript

Laboratory Corporation of America Holdings (NYSE:LH) Q4 2023 Earnings Conference Call February 15, 2024 9:00 AM ET

Company Participants

Christin O'Donnell - VP of IR
Adam Schechter - Chairman and CEO
Glenn Eisenberg - EVP and CFO

Conference Call Participants

Jack Meehan - Nephron Research
Kevin Caliendo - UBS
Erin Wright - Morgan Stanley
Stephanie Davis - Barclays
Patrick Donnelly - Citi
Brian Tanquilut - Jefferies
Pito Chickering - Deutsche Bank
Elizabeth Anderson - Evercore ISI
Eric Coldwell - Baird
Lisa Gill - JPMorgan
John Kim - Bank of America Merrill Lynch

Operator

Good day and welcome to the Laboratory Corporation of America Holdings Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation there will be a question-and-answer session. [Operator Instructions] Please be advised, today's conference is being recorded.

I'd now like to hand the conference over to your speaker today, Christin O'Donnell, Vice President, Investor Relations, please go ahead.

Christin O'Donnell

Thank you, operator. Good morning and welcome to Labcorp’s fourth quarter 2023 conference call. As detailed in today's press release, there will be a replay of this conference call available via telephone and internet. With me today are Adam Schechter, Chairman and Chief Executive Officer and Glenn Eisenberg, Executive Vice President and Chief Financial Officer.

This morning in the Investor Relations section of our website at www.labcorp.com we posted both our press release and an investor relations presentation with additional information on our business and operations, which include a reconciliation of the non-GAAP financial measures to the most comparable GAAP financial measures, both of which are discussed during today's call.

Additionally, we are making forward-looking statements. These forward-looking statements include, but are not limited to statements with respect to the estimated 2023 guidance and the related assumptions, the recently